Guadeloupe vs Montserrat: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Guadeloupe
0.2%
in 2024
Montserrat
0.2%
in 2024
Guadeloupe rank
98th
Montserrat rank
98th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Guadeloupe
- Montserrat
How they compare
Guadeloupe currently reports 0.2% against 0.2% in Montserrat, a difference of 0.0%.
Across all 10 years both countries report, Montserrat has been ahead every year.
Guadeloupe ranks 98th and Montserrat ranks 98th of 246 countries.
Head to head by decade
| Decade | Guadeloupe | Montserrat | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.3% | 0.3% | 0.0% | — |
| 2020s | 0.2% | 0.2% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Guadeloupe or Montserrat?
- Guadeloupe, at 0.2% against 0.2% in Montserrat as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Guadeloupe and Montserrat?
- 0.0%, with Guadeloupe ahead.
- How many years of comparable data are there for Guadeloupe and Montserrat?
- 10 years are reported by both, from 2015 to 2024.
- How do Guadeloupe and Montserrat rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Guadeloupe ranks 98th and Montserrat ranks 98th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.